Raises question of what to do with additional variants.
This week, a panel of outside experts gathered at the Food and Drug Administration (FDA) headquarters to discuss how to apply future booster doses to the continually mutating COVID-19 coronavirus. FDA officials made clear that there is a lot that they do not know, but communicated what they do know; that the currently developed vaccines are not well-matched to the current sub-variant BA.2, and that future sub-variants will likely align with current vaccines even less.
With that knowledge, developing a strategy to create usable guidelines is a challenging task. “This discussion today is a much larger discussion – it’s a discussion for what do we do about the entire population, and what do we do when we think the virus has evolved further,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.
As the Lord Leads, Pray with Us…
- For FDA Commissioner Califf as he oversees the agency’s approvals and authorizations.
- For CDC Director Walensky as she manages the data and information on the virus and other public health threats.
- For scientists and researchers evaluating the effectiveness of the COVID inoculations.
Sources: The Hill, Reuters
